NDA 021307 · Bayer Healthcare LLC
Lotrimin Ultra
Butenafine Hydrochloride · Topical
Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Dec 7, 2001
Approved uses
2
Original approval plus efficacy supplements
Registered trials
8
4 Phase 3, 0 recruiting
FAERS reports
578
61 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 5, 2025.
Uses cures most jock itch relieves itching, burning, cracking, and scaling which accompany this condition
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 17, 2014 Supplement 14 · Efficacy Letter
- Dec 7, 2001 Original approval · Type 8 - Partial Rx to OTC Switch LetterReviewLabel
1 products under this application
- LOTRIMIN ULTRA · BUTENAFINE HYDROCHLORIDE 1% · CREAM, TOPICAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Butenafine" as an intervention, any sponsor and status, largest first.
- Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea PedisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01580878 · 707 participants · Start Jan 2012 · Primary completion Aug 2012
Drug: Butenafine Hydrochloride Cream, 1%; Lotrimin Ultra® and 1 more · For: Tinea Pedis
- Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea PedisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT00835510 · 548 participants · Start Jun 2008 · Primary completion Oct 2008
Drug: Butenafine cream 1% manufactured by Taro; Lotrimin Ultra (butenafine) 1% and 1 more · For: Tinea Pedis
Sites: Burbank, California; San Diego, California; Miami, Florida · 17 sites in all
- Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea PedisPivotal-lookingTerminated
Sun Pharmaceutical Industries, Inc.Industry
NCT01119742 · 428 participants · Start Jul 2010 · Primary completion Mar 2011
Drug: Butenafine Hydrochloride 1%; Butenafine Hydrochloride 1% B and 3 more · For: Interdigital Tinea Pedis
- Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT04531540 · 225 participants · Start Sep 9, 2013 · Primary completion Oct 18, 2013
Drug: Butenafine HCl 1% (BAY1896425) · For: Hypersensitivity
Sites: Fairfield, New Jersey
- Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy ParticipantsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT04532164 · 137 participants · Start Jun 10, 2013 · Primary completion Nov 11, 2013
Drug: Butenafine HCl 1% (BAY1896425) - Induction Phase; Butenafine HCl 1% (BAY1896425) - Challenge Phase · For: Dermatitis, Photoallergic
Sites: Fairfield, New Jersey
United LaboratoriesIndustry
NCT03999437 · 42 participants (planned) · Start Jan 2, 2019 · Primary completion Dec 13, 2019
Drug: TERBINAFINE HYDROCHLORIDE (1%); BUTENAFINE HYDROCHLORIDE (1%) and 1 more · For: Tinea Pedis
Sites: City of Muntinlupa, Philippines
- Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human SubjectsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT04531527 · 32 participants · Start Jun 24, 2013 · Primary completion Jun 28, 2013
Drug: Butenafine HCl 1% (BAY1896425) · For: Dermatitis, Phototoxic
Sites: Fairfield, New Jersey
- Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT04531813 · 32 participants · Start Jun 10, 2013 · Primary completion Jul 1, 2013
Drug: Butenafine HCl 1% (BAY1896425); Positive Control-Sodium lauryl sulfate (SLS) · For: Hypersensitivity
Sites: Fairfield, New Jersey
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective185
- off label use59
- product use issue43
- product use in unapproved indication34
- pruritus33
- condition aggravated29
- rash21
- drug ineffective for unapproved indication20
- drug effective for unapproved indication19
- erythema19
- drug effect decreased18
- product administered at inappropriate site15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 41 |
| 2013 | 81 |
| 2014 | 61 |
| 2015 | 25 |
| 2016 | 31 |
| 2017 | 41 |
| 2018 | 42 |
| 2019 | 32 |
| 2020 | 28 |
| 2021 | 24 |
| 2022 | 27 |
| 2023 | 38 |
| 2024 | 30 |
| 2025 | 39 |
| 2026 | 29 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2014 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2008 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2011 · Systematic Review
- Are placebo-controlled trials of creams for athlete's foot still justified?
Crawford F, Harris R, Williams HC · Br J Dermatol 2008 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis.
Reyes BA, Beutner KR, Cullen SI, et al. · Int J Dermatol 1998 · Clinical Trial, Multicenter Study
- Comparison of superficial mycosis treatment using Butenafine and Bifonazole nitrate clinical efficacy.
Abdul Bari MA · Glob J Health Sci 2012 · Comparative Study, Randomized Controlled Trial
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.